New perspectives on developing acute stroke therapy
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The development of additional acute stroke therapies to complement and supplement intravenous recombinant tissue‐type plasminogen activator within the first 3 hours after stroke onset remains an important and pressing need. Much has been learned about the presumed target of acute stroke therapy, the ischemic penumbra, and clinically available imaging modalities such as magnetic resonance imaging and computed tomography hold great promise for at least partially identifying this region of potentially salvageable ischemic tissue. Understanding the biology of ischemia‐related cell injury has also evolved rapidly. New treatment approaches to improve outcome after focal brain ischemia will likely be derived by looking at naturally occurring adaptive mechanisms such as those related to ischemic preconditioning and hibernation. Many clinical trials previously performed with a variety of neuroprotective and thrombolytic drugs provide many lessons that will help to guide future acute stroke therapy trials and enhance the likelihood of success in future trials. Combining knowledge from these three areas provides optimism that additional acute stroke therapies can be developed to maximize beneficial functional outcome in the greatest proportion of acute stroke patients possible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interobserver agreement for the assessment of handicap in stroke patients
van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988) · Stroke · doi:10.1161/01.str.19.5.604 · Cited by 6,512
Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)08020-9 · Cited by 3,662
Adams, H. P., Davis, P. H., Leira, E. C., Chang, K.-C., Bendixen, B. H., Clarke, W. R., Woolson, R. F., & Hansen, M. D. (1999) · Neurology · doi:10.1212/wnl.53.1.126 · Cited by 1,456 · cited 1×
“It is now apparent that patients with mild initial deficits (NIHSS scores of 4–7) have a high rate of spontaneous improvement without treatment and severely affected patients (NIHSS scores 20) have a poor natural history.(58,59) Including too many mild patients in a clinical trial will increase the placebo responder r…”
BackgroundViability thresholds and the penumbra of focal ischemia
Hossmann, K. (1994) · Annals of Neurology · doi:10.1002/ana.410360404 · Cited by 1,370 · cited 1×
“centage of the ischemic lesion is potentially salvageable with timely and appropriate therapy.(6) This idea of potentially salvageable ischemic tissue is directly related to the concept of the ischemic penumbra and the existence of a therapeutic time window after stroke onset.”
BackgroundMechanism, origin, and evolution of anoxia tolerance in animals☆
Hochachka, P. W., & Lutz, P. L. (2001) · Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology · doi:10.1016/s1096-4959(01)00408-0 · Cited by 500
Heiss, W.-D., Graf, R., Löttgen, J., Ohta, K., Fujita, T., Wagner, R., Grond, M., & Weinhard, K. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199704000-00004 · Cited by 132 · cited 1×
“Initial PET studies were performed in cat and primate stroke models, and the studies then were extended into stroke patients.(8,9) PET studies performed in stroke patients up to 18 hours after onset demonstrated the existence of substantial volumes of ischemic tissue with cerebral metabolic rate of oxygen consumption…”
MethodAn Overview of Acute Stroke Therapy: Past, Present, and Future
Fisher, M., & Schaebitz, W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3196 · Cited by 112
Self-citation
Cited by
Wegener, S., Gottschalk, B., Jovanovic, V., Knab, R., Fiebach, J. B., Schellinger, P. D., Kucinski, T., Jungehülsing, G. J., Brunecker, P., Müller, B., et al. (2004) · Stroke · doi:10.1161/01.str.0000115767.17923.6a · Cited by 303
Repairing the human brain after stroke. II. Restorative therapies
Cramer, S. C. (2008) · Annals of Neurology · doi:10.1002/ana.21412 · Cited by 285
Future of neuroprotection for acute stroke: In the aftermath of the SAINT trials
Savitz, S. I., & Fisher, M. (2007) · Annals of Neurology · doi:10.1002/ana.21127 · Cited by 267
“Combining neuroprotection with reperfusion therapy could be synergistic and maximize ischemic tissue salvage.(7) Numerous animal studies of a wide variety of neuroprotective drugs have shown substantial amounts of ischemic tissue salvage in permanent occlusion stroke models with delayed initiation of therapy, providin…”
BackgroundSelf-citationDiNapoli, V. A., Huber, J. D., Houser, K., Li, X., & Rosen, C. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.12.007 · Cited by 172
“stroke patient, as these methods have consistently identified promising neuroprotective candidates that have failed in clinical trails (Fisher, 1999; Gladstone et al., 2002; Fisher and Ratan, 2003).”
BackgroundMethodFisher, M. (2005) · Stroke · doi:10.1161/01.str.0000173403.60553.27 · Cited by 156
Self-citation
Metadata
- Authors
- Fisher, M., & Ratan, R.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2002-11-25
- Volume
- 53
- Issue
- 1
- Pages
- 10-20
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2089585471
- Cited by
- 94
- References
- 7
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.